Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D04INS
|
||||
Former ID |
DIB004813
|
||||
Drug Name |
Long-acting exenatide
|
||||
Synonyms |
HM-11260C; LAPS-Exendin; LAPS-Exendin-4; Long-acting exenatide (LAPS, type 2 diabetes); Long-acting exenatide (LAPS, type 2 diabetes), Hanmi; DM-exendin-4(Lys27)-PEG-Fc; Long-acting exendin-4 analog (LAPS, type 2 diabetes), Hanmi; Des-amino-histidyl exendin-4(Lys)-PEG-immunoglobulin Fc
|
||||
Company |
Hanmi pharmaceutical
|
||||
Structure |
Download2D MOL |
||||
Canonical SMILES |
N1(C(=O)[C@H]2N(C(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC(=O)[<br />C@@H](NC(=O)[C@H]3N(C(=O)CNC(=O)CNC(=O)[C@H](CC(=O)N)CC<br />(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O<br />)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@<br />@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]<br />(NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC<br />(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O<br />)[C@@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC(=O)CN)CCC(=<br />O)O)[C@H](O)C)Cc4ccccc4)[C@H](O)C)CO)CC(=O)O)CC(C)C)CO)<br />CCCCN)CCC(=O)N)CCSC)CCC(=O)O)CCC(=O)O)CCC(=O)O)C)C(C)C)<br />CCCNC(=N)N)CC(C)C)Cc4ccccc4)[C@H](CC)C)CCC(=O)O)Cc4c[nH<br />]c5c4cccc5)CC(C)C)CCCCNC(=O)*)CCC3)CO)CO)C)CCC2)[C@H](C<br />(=O)N2[C@H](C(=O)N[C@H](C(=O)N)CO)CCC2)CCC1
|
||||
Target and Pathway | |||||
Target(s) | Glucagon-like peptide 1 receptor | Target Info | Agonist | [530376], [532841] | |
References | |||||
Ref 530376 | Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics)--preclinical and clinical results. Best Pract Res Clin Endocrinol Metab. 2009 Aug;23(4):463-77. | ||||
Ref 532841 | Bydureon: first once weekly GLP-1 receptor agonist (exenatide LAR). Rev Med Liege. 2014 Apr;69(4):214-9. | ||||
Ref 551186 | 2005 approvals: Safety first. Nature Reviews Drug Discovery 5, 92-93 (February 2006). | ||||
Ref 530376 | Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics)--preclinical and clinical results. Best Pract Res Clin Endocrinol Metab. 2009 Aug;23(4):463-77. | ||||
Ref 532841 | Bydureon: first once weekly GLP-1 receptor agonist (exenatide LAR). Rev Med Liege. 2014 Apr;69(4):214-9. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.